Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-guanidinium-7-aminoheptane
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
A synthetic small molecule, 1-guanidinium-7-aminoheptane is an experimental compound primarily studied as a potent inhibitor of deoxyhypusine synthase, an enzyme involved in the post-translational activation of eukaryotic initiation factor 5A (eIF5A). By inhibiting this enzyme, the compound interferes with hypusination—a unique modification essential for cell proliferation and protein synthesis. It has not been approved for any clinical indication and remains at the investigative stage[1][2][3].
- Other names
- 1-Guanidinium-7-AminoheptaneAC1NRBDQAC-1NRBDQAC 1NRBDQN-(7-aminoheptyl)methanetriamineN"-(7-aminoheptyl)methanetriamineGC7GC-7GC 7
02
Targets
DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on 1-guanidinium-7-aminoheptane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-guanidinium-7-aminoheptane.